| The1 main reason of the failure in the cancer clinical chemotherapy is multidrug- resistance. P-gp,Bcl-2,GST-π,Topo πⅡ have been proposed as the responsible for multidrug-resistance This study expect to fill unstandard the expression of P- gp,Bcl-2,GST-π,Topo Ⅱ in malignant and non-malignant breast tissue, and the relationship between the four drugresistance-associated proteins and drug-sensitivity of breast cancer cells in vitro. The article evaluated the expression of P-gp,Bcl-2,GST-π,Topo Ⅱ in fifty-two samples ( 28 invasive breast cancers, 4 breast cancers in situ, 10 breast adenomas, 10 normal breast ) by means of quantitative immunohistochemical image analysis . we found the expression of Topo Ⅱ increased significantly in invasive cancer compared with the non-malignant samples and cancer in situ(P<0.0 1), and it was significantly associated with axillary node postive, low age. The expression of Bcl-2 decreased significantly in invasive cancer compared with breast adenoma (P<0.05). The expression of GST- it decreased significantly in invasive cancer compared with the non- malignant (P<0.05). The expression of ERPR decreased significantly in invasive cancer compared with non- malignant breast samples (P<0.05 , P<0.01). No significant difference in the expression of P-gp has been observed between non-malignant and malignant breast samples. A highly significant linear correlation was found between Bcl-2 and ER.. PR (r=0. 56, P<0. 001, n=52; r=0.54,P<0.001,n=52),and a positive correlation also was observed between GST-it and ER (r=0.47, P<0.O01, n=52) In addtion, this study used the MTTassay to assessthechemosensitivity to 24 breast invasive ductal cancers with four cytotoxic drugs ( ADR, VCR, CTX, 3 5-FU). The expression of P-gp in ADR ,CTX, 5-FU unresponsive tumors showed higher levels compared with those of responsive tumors(P |
PDF Full Text Request